Current Clinical Trials

  • Home
  • Current Clinical Trials

Current Clinical Trials

Clinical Trials Currently Available for PTCL and CTCL Patients:

Clinical Trials

NCT01590732

Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

View Clinical Trial Information

NCT01482962

Alisertib (MLN8237) or Investigator’s Choice in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

View Clinical Trial Information

NCT01796002

Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma

View Clinical Trial Information

NCT01352520

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

View Clinical Trial Information

NCT01336920

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

View Clinical Trial Information

NCT01777152

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

View Clinical Trial Information

NCT01738594

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

View Clinical Trial Information

NCT01578499

A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

View Clinical Trial Information

NCT01728805

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

View Clinical Trial Information

NCT01626664

KW-0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

View Clinical Trial Information

NCT00047060

SCT Therapy with Campath-1H for Treating Advanced Mycosis Fungoides (MF) and Sezary Syndrome (SS)

View Clinical Trial Information

NCT01805037

Phase I/II Study of Brentuximab Vedotin + Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

View Clinical Trial Information

NCT01660451

Open-label, Uncontrolled Phase II Trial of Intravenous P13K Inhibitor BAY80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas

View Clinical Trial Information

NCT01567709

Alisertib in Combination with Vorinostat in Treating Patients with Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma or Peripheral T-Cell Lymphoma

View Clinical Trial Information

NCT01431209

Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma

View Clinical Trial Information

NCT01678443

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies

View Clinical Trial Information

NCT01261247

Panobinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

View Clinical Trial Information

NCT01703949

Brentuximab Vedotin in Treating Patients with Relapsed or Refractory CD30+ Lymphoma

View Clinical Trial Information

NCT02567656

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

View Clinical Trial Information

NCT01871727

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

View Clinical Trial Information

NCT02495415

To address the hypothesis that intermittent treatment with fenretinide intravenous emulsion will induce objective responses in patients with PTCL.

View Clinical Trial Information

NCT02448381

To evaluate the use of SGX301 to treat patients with patch/plaque phase cutaneous T-cell lymphoma.

View Clinical Trial Information

NCT02580552

This is a two-part study to evaluate the safety of MRG-106 in patients with CTCL, mycosis fungoides subtype.

View Clinical Trial Information

NCT02464228

This study is designed to investigate the antitumor activity of tipifarnib in subjects with advanced PTCL.

View Clinical Trial Information

NCT02309580

This is a Phase 1 clinical trial to find out whether ibrutinib is safe in patients with relapsed and refractory T-Cell non-Hodgkin lymphoma.

View Clinical Trial Information

NCT02588651

This study will include patients with MTCL that has been treated with at least one type of chemotherapy, but is not responding.

View Clinical Trial Information

NCT02594267

To evaluate the maximum tolerated dose of pralatrexate in combination with CHOP regimen in patients with newly diagnosed PTCL.

View Clinical Trial Information

NCT02192021

This study is to test if MNA-directed chemo-immunotherapy using doxorubicin will kill tumor cells locally to induce durable systemic immnunity. 

View Clinical Trial Information

NCT01902225

This is a Phase 1 efficacy study of the combination of romidepsin in combination with Doxil for adult patients with relapsed or refractory CTCL.

View Clinical Trial Information

NCT01897012

This phase 1 trial studies the side effects and best dose of alisertib and romidepsin in treating patients with relapsed or refractory t-cell lymphoma. 

View Clinical Trial Information

NCT01738594

This randomized phase 1 trial studies the side effects and best dose of carfilzomib when given with or without romidepsin in treating CTCL.

View Clinical Trial Information

NCT02783625

The purpose of this study is to test the safety of a study drug called duvelisib.

View Clinical Trial Information

NCT02158975

The purpose of this study is to determine the extent to which MLN9708 inhibits GATA-3 expression, and whether it represents a biomarker for MLN9708.

View Clinical Trial Information

NCT02342782

This trial studies the side effects and best dose of yttrium Y 90 basiliximab when given with standard chemotherapy before a stem cell transplant.

View Clinical Trial Information

NCT02168140

This trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in different conditions. 

View Clinical Trial Information

NCT02535247

This is a multicenter, single-arm, open label 2-stage phase 2 study exploring monotherapy with the PD-1 antibody pembrolizumab in patients with PTCL.

View Clinical Trial Information

NCT01947140

This is a study to test how safe the combination of romidepsin and pralatrexate are in patients with lymphoid malignancies and determine dosage.

View Clinical Trial Information

NCT01998035

This is a dose escalation study with an initial phase 1 followed by a disease focused phase 2.  Its primary objective is to determine MTD and DLT.

View Clinical Trial Information

NCT02520791

This phase 1 trial studies the side effects and best dose of ICOS monoclonal antibody MEDI-570 in treating patients with PTCL follicular variant.

View Clinical Trial Information

NCT01431209

This phase 2 trial studies how well giving ruxolitinib phosphate works in treating patients with peripheral T-cell non-hodgkin lymphoma.

View Clinical Trial Information

NCT02232516

The purpose of this study is to evaluate how safe and effective the combination of romidepsin and lenalidomide is for treating patients with PTCL.

View Clinical Trial Information

NCT02341014

This is an open label phase 1b/2a study of patients with relapsed/refractory B- and T-cell lymphomas who are treated in a 3+3 design.

View Clinical Trial Information

NCT02142530

This research study is evaluating carfilzomib in combination with belinostat with participants who have relapsed or refractory non-Hodgkin Lymphoma.

View Clinical Trial Information

NCT02561273

This phase 1/2 trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy in patients with NHL.

View Clinical Trial Information

NCT02576496

This study is to evaluate the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed or refractory hematologic malignancies.

View Clinical Trial Information

NCT02061449

To evaluate the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation agains Poly ICLC.

View Clinical Trial Information